Calidi trims staff, banks $1.2m and eyes 2027 first dosing for CLD-401

Calidi Biotherapeutics ended the third quarter of 2026 with $3.9m in cash, a thin balance for a company still preparing its lead programme for human testing. It reported a net loss of $3.6m for the period on 13 November. The two figures are of similar size, although a net loss is not the same as cash burn, so the filing detail would be needed to gauge how long the money lasts.

Management has moved to cut spending. General and administrative expenses fell 39% in the quarter, though the summary available to CompePharma did not state the comparison period. On 6 November, after the quarter closed, Calidi restructured, mainly by reducing headcount. It expects the changes to save about $3m a year. The company also raised $1.2m through an at-the-market registered direct offering.

The cuts and the raise sit alongside a pipeline that remains preclinical. CLD-401, Calidi's lead oncolytic virus candidate, is still in studies intended to support an investigational new drug application. Preclinical data were presented at ESMO 2026. The company is aiming to dose its first patient in the second half of 2027.

CompePharma has seen only the company's results summary. Detail on the cost base, the scale of the staff reduction, the terms of the offering and the steps remaining before an IND filing was not available, and we have not filled those gaps.